BEXSERO
Multicomponent Meningococcal B Vaccine
(recombinant, adsorbed)

Multicomponent Meningococcal B Vaccine
(recombinant, adsorbed)
MenB average annual incidence rates in Canada,* 2007-2011 1
Adapted from the 2014 PHAC NACI statement 1
*BEXSERO is indicated for active immunization of individuals from 2 months through 25 years old against invasive disease caused by Neisseria meningitidis serogroup B strains. BEXSERO is not indicated for use in individuals >25 years of age.
BEXSERO is not expected to provide protection against all circulating meningococcal serogroup B strains. Protection against IMD caused by other serogroups has not been studied. Therefore, protection against other serogroups should not be assumed with BEXSERO. As with any vaccine, BEXSERO may not protect all vaccine recipients.
Percentage of reported IMD cases by serogroup (2013-2017; N=548) 3†
* Meningococcal disease caused by Neisseria meningitidis group B strains.
† Based on most recent data available
* BEXSERO is indicated for active immunization of individuals from 2 months through 25 years old against invasive disease caused by Neisseria meningitidis serogroup B strains. BEXSERO is not indicated for use in individuals >25 years of age.
BEXSERO is not expected to provide protection against all circulating meningococcal serogroup B strains. Protection against IMD caused by other serogroups has not been studied. Therefore, protection against other serogroups should not be assumed with BEXSERO. As with any vaccine, BEXSERO may not protect all vaccine recipients.
This page is for Healthcare Professionals only. If you are not a Healthcare Professional, please visit Bexsero.ca.